Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNP-2092 Tissue Distribution in Hip or Knee Arthroplasty
NCT04294862Phase 1Completed
- Sponsor
- TenNor Therapeutics
- Start
- Mar 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rifaquizinone in prosthetic joint infection (PJI), sponsored by TenNor Therapeutics. Primary endpoints: Concentration of TNP-2092 in synovial fluid and Concentration of TNP-2092 in bone. Started Mar 2021; status: completed.
02
Drugs
rifaquizinone
03
Conditions
prosthetic joint infection (PJI)
Beyond the preview
Go deeper on NCT04294862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04294862.